You are here

Keytruda

Merck bags adjuvant okay for Keytruda in melanoma

Merck bags adjuvant okay for Keytruda in melanoma

Pharmaforum

Flag link:

Merck increased list prices on Keytruda, Gardasil in November

Merck increased list prices on Keytruda, Gardasil in November

Biopharma Dive

Flag link:

One more shot at slowing Keytruda’s first-line lung cancer domination

One more shot at slowing Keytruda’s first-line lung cancer domination

EP Vantage

Flag link:

Merck's Keytruda picks up first-in-class survival win in esophageal cancer

Merck's Keytruda picks up first-in-class survival win in esophageal cancer

Fierce Pharma

esophageal cancer

Flag link:

GSK pancreatic cancer drug heads to phase 1 combo with Merck's Keytruda after positive mouse trial

GSK pancreatic cancer drug heads to phase 1 combo with Merck's Keytruda after positive mouse trial

Fierce Biotech

pancreatic cancer

Flag link:

Merck gets FDA okay for Keytruda as liver cancer therapy

Merck gets FDA okay for Keytruda as liver cancer therapy

Pharmaforum

hepatocellular carcinoma

Flag link:

OncoSec’s defense of weak preliminary Tavo data for PD-1 resistant melanoma can’t stop a rout

OncoSec’s defense of weak preliminary Tavo data for PD-1 resistant melanoma can’t stop a rout

Endpoints

Flag link:

FDA Action Alert: EyePoint Pharma and Merck

FDA Action Alert: EyePoint Pharma and Merck

BioSpace

posterior segment uveitis

advanced hepatocellular carcinoma

Flag link:

Merck's Keytruda secures broader lung cancer approval

Merck's Keytruda secures broader lung cancer approval

Biopharma Dive

squamous non-small cell lung cancer

Flag link:

ESMO: Merck's Keytruda, alone and in combo, makes its case for earlier use in head and neck cancer

ESMO: Merck's Keytruda, alone and in combo, makes its case for earlier use in head and neck cancer

Fierce Pharma

head and neck cancer

Flag link:

ESMO18: Merck’s STING agonist lacks bite on its own

ESMO18: Merck’s STING agonist lacks bite on its own

Fierce Biotech

Flag link:

Why Merck's Latest Success Means Trouble for Exelixis Inc.

Why Merck's Latest Success Means Trouble for Exelixis Inc.

Yahoo/Motley Fool

Flag link:

Merck's Keytruda, ready to challenge Bristol-Myers Squibb, posts kidney cancer combination win

Merck's Keytruda, ready to challenge Bristol-Myers Squibb, posts kidney cancer combination win

Fierce Pharma

Flag link:

Merck follows Opdivo’s suit, prices Keytruda in China at half its U.S. tag

Merck follows Opdivo’s suit, prices Keytruda in China at half its U.S. tag

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Merck's Keytruda clocks up new win as EU approves chemo cocktail

Merck's Keytruda clocks up new win as EU approves chemo cocktail

Yahoo/Reuters

advanced non-squamous non-small cell lung cancer

Flag link:

Merck's Keytruda threatens Pfizer, Merck KGaA's Bavencio with Merkel cell 'priority' tag

Merck's Keytruda threatens Pfizer, Merck KGaA's Bavencio with Merkel cell 'priority' tag

Fierce Pharma

Merkel cell carcinoma

Flag link:

FDA gives Merck ‘real-time’ OK for Keytruda, offering a peek at the latest extension of the agency’s data express highway

FDA gives Merck ‘real-time’ OK for Keytruda, offering a peek at the latest extension of the agency’s data express highway

Endpoints

non-squamous non-small cell lung cancer

Flag link:

After an epic battle of blockbusters, Merck leapfrogs Bristol-Myers to take the lead on PD-1/L1 market

After an epic battle of blockbusters, Merck leapfrogs Bristol-Myers to take the lead on PD-1/L1 market

Endpoints

Bristol-Myers Squibb

Flag link:

Keytruda Becomes the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma

Keytruda Becomes the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma

CP Wire

Flag link:

Keytruda Becomes the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma

Flag link:

Pages